Thursday, November 22, 2018 2:10:48 PM
I disagree that Sawston brings in that much. There are 3 notes and a toxic waste liability attached to it.
They again rolled the 12% mortgages for another year, and paid 3% to do so. That implies to me they can not pull the equity out via a refinance, else why pay these rates?
And everybody here has convinced me that LP will not sell
100% DISAGREE due not only to your, demonstrated by many here, of spin and distortions for the uninformed.
MORE Importantly what EXwan points out defies my real world experience in a similar experience to Sawston/CEO Linda Powers situation NOW.
After I worked for two decades at the world headquarters for Top Tier Wall St firms along with being a Money Manager I was a real estate developer and made money in a difficult real estate downturn where I witnessed many bankruptcies pre 1995:
I was able in the worst real estate downturn to renegotiate a LARGE loan with 15% mortgage rates, a boost of THREE %, and extended the loan for another year and had the bank agree to NO early prepayment penalty.
Through the sale of ONE of the properties secured by this loan I was able to extinguish the entire loan in two months!
So the parallels fit: CEO pulls rabbits out of the hat like I have.
The coming TSUNAMI(Partnership to give NWBO money money money and needed ENDORSEMENT and CREDIBILITY for marketplace validation and future valuation will, should it happen restore and catapult the valuation just like what happened recently to my AMRN and bury those Shorts/FUDDERS ... especially AFRAUDSTEIN etc.
ALL for mankind; patients and Game Changer in Oncology: With DCVAX L’s demonstrated Efficacy/Minor SAE’s and much lower costs
vs what’s been FDA approved.
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
